Founded in 2011 with a mission to both discover and develop internal candidates while also in-licensing mid-stage candidates from other companies, the two-fold strategy of Ascletis Inc. began to reach fruition July 12 with the announcement of a licensing deal for an RNA-interference candidate for hepatocellular carcinoma (HCC) from U.S. biotech Alnylam Pharmaceuticals Inc.
Alnylam, one of the pioneer firms in RNAi, advanced ALN-VSP through Phase I in liver cancer but, due to the size of the patient population and the cost of developing cancer therapeutics, decided its best path forward with the drug was by collaborating with a partner willing to take on the costs of development Also see "
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?